Drug Research
With a $400M Deal: Ideaya Targets Biocytogens BsADC Program
For an option on Biocytogen Pharmaceuticals' possible first-in-class B7H3/PTK7 BsADC program, Ideaya Biosciences is paying more than $400 million. The goal of antibody drug conjugates (ADCs) is to give highly focused therapy by combining the cytotoxic medicines with the...
Drug Research
Eli Lilly Invests In Actinium-225 To Support Radiopharma
The largest pharmaceutical company in the world based on market value, Eli Lilly, is getting into the nuclear isotope manufacturing industry as cancer medicine manufacturers want to ensure a supply of radioactive elements essential to the developing area of...
Drug Research
Regulatory Challenges In Radiopharmaceuticals And The CAGT
The life sciences industry is going through a big change right now, thanks to the fast growth of new treatments like cell and gene therapies (CAGT) and big new investments in radiopharmaceuticals. These new ideas have the ability to...
Drug Research
IAEA Unveils New Database For Global Radiopharmaceuticals
Research, cooperation, and the sustainability of safe radiopharmaceuticals for clinical application will be aided by a new IAEA radiopharmacy database. To compile into the new online database, the IAEA is now gathering data on facilities that manufacture medical radioisotopes...
Drug Research
How Are ADCs Improving Cancer Treatments With Precision
ADCs could lead to better and more efficient treatments in the complex and specialized field of tailored cancer medicines. ADCs are made up of a monoclonal antibody that is permanently linked to a lethal drug. They were created as...
Drug Research
Antibody Drug Conjugates: Future Therapies And Treatment
Beyond cancer, there are a number of sectors that provide considerable prospects for antibody drug conjugates (ADCs), using their capacity to deliver therapeutic drugs selectively to sick cells or tissues while avoiding off-target effects. These opportunities may be used...
Drug Research
Advancements In ADCs: Important Trends And Market Insights
Antibody drug conjugates (ADCs) are the main players in the fields of cancer clinical research and deal-making, with new alliances and contracts appearing on a regular basis. Businesses set themselves apart as the ADC market grows increasingly saturated by...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read